Zetia (Ezetimibe) and Diphenhydramine Interaction: What Clinicians and Patients Should Know

Why This Combination Raises Questions

Patients prescribed ezetimibe for hyperlipidemia frequently reach for over-the-counter diphenhydramine to manage seasonal allergies, insomnia, or cold symptoms. That overlap is common: roughly 31.7% of U.S. adults aged 40 to 75 take a statin or non-statin lipid-lowering agent, according to NCHS data published in 2023 [1]. Diphenhydramine, meanwhile, ranks among the most widely purchased OTC antihistamines in the United States, with an estimated 20% of adults using a first-generation antihistamine at least once annually [2].

The concern is reasonable. Ezetimibe's FDA-approved label notes interactions with cyclosporine, fibrates, and cholestyramine [3]. Diphenhydramine carries a well-documented anticholinergic and CNS-depressant profile that complicates polypharmacy in older adults [4]. Patients and providers often wonder whether combining these two agents introduces hidden pharmacokinetic or pharmacodynamic risks. The short answer: for most adults, it does not. But the longer answer requires examining the metabolic pathways of each drug, the pharmacodynamic overlap in specific populations, and the monitoring thresholds that separate safe co-administration from avoidable adverse events.

Ezetimibe Pharmacokinetics: A Glucuronidation-Dependent Drug

Ezetimibe is absorbed in the small intestine, where it selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter at the brush border [3]. After absorption, the drug undergoes rapid and extensive Phase II conjugation. UGT1A1 and UGT1A3 convert ezetimibe to its pharmacologically active glucuronide metabolite, ezetimibe-glucuronide, which accounts for the majority of circulating drug [5].

This matters for interaction risk. Unlike statins such as atorvastatin or simvastatin, which depend heavily on CYP3A4, ezetimibe has minimal CYP450 involvement. A study by Kosoglou et al. confirmed that ezetimibe does not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2D6, or CYP3A4 at therapeutic concentrations [5]. The drug also undergoes enterohepatic recirculation, which extends its effective half-life to approximately 22 hours and maintains steady intestinal concentrations of the active glucuronide [3].

The clinical relevance: drugs that primarily interact through CYP450 inhibition or induction have a low probability of altering ezetimibe exposure. Diphenhydramine falls squarely into this category.

Diphenhydramine Pharmacokinetics: CYP2D6 and Anticholinergic Load

Diphenhydramine is a first-generation H1 antihistamine metabolized primarily by CYP2D6, with secondary contributions from CYP1A2 and CYP2C9 [6]. It acts as a moderate CYP2D6 inhibitor, which can raise plasma levels of CYP2D6 substrates such as metoprolol, codeine prodrug activation, and certain SSRIs [4]. Its elimination half-life ranges from 2.4 to 9.3 hours in healthy adults and may extend beyond 13 hours in elderly patients [6].

Beyond histamine blockade, diphenhydramine crosses the blood-brain barrier readily, producing sedation and cognitive impairment. It also exerts muscarinic receptor antagonism, contributing to the anticholinergic burden that the American Geriatrics Society (AGS) Beers Criteria flags as "potentially inappropriate" in adults 65 and older [7]. The 2023 AGS Beers Criteria update specifically lists diphenhydramine as a drug to avoid in older adults because of its "highly anticholinergic" profile, with a "strong" recommendation quality rating [7].

None of these metabolic characteristics intersect meaningfully with ezetimibe's glucuronidation pathway. CYP2D6 inhibition by diphenhydramine does not alter ezetimibe clearance because ezetimibe is not a CYP2D6 substrate. The reverse also holds: ezetimibe does not inhibit CYP2D6 and therefore does not change diphenhydramine exposure [5].

Formal Interaction Classification: What the Databases Report

Major drug interaction databases assign this pair a low severity rating. Neither the FDA label for ezetimibe (Zetia) nor the FDA label for diphenhydramine lists the other drug as a known interactant [3][6]. The Lexicomp database classifies ezetimibe-diphenhydramine as a "no known interaction" pair. Clinical Pharmacology (Elsevier) returns no documented pharmacokinetic interaction.

This is consistent with the metabolic independence described above. For comparison, ezetimibe's labeled interactions include cyclosporine (increases ezetimibe AUC by 3.4-fold), fenofibrate (increases ezetimibe AUC by approximately 1.5-fold), and cholestyramine (decreases ezetimibe AUC by 55%) [3]. These interactions involve either biliary secretion, enterohepatic recirculation disruption, or direct changes in glucuronidation. Diphenhydramine affects none of these pathways.

The absence of a cataloged interaction does not mean zero risk. It means the pharmacokinetic interaction probability is below the threshold that warrants labeling or dose modification. Pharmacodynamic considerations, addressed in the next section, apply separately.

Pharmacodynamic Considerations: Anticholinergic Burden and GI Motility

While the pharmacokinetic profile is reassuring, pharmacodynamic overlap deserves attention in certain populations. Diphenhydramine carries an Anticholinergic Cognitive Burden (ACB) score of 3, the highest tier, indicating definite anticholinergic activity [8]. Ezetimibe itself has no anticholinergic properties. The concern arises when patients taking diphenhydramine alongside multiple other medications accumulate a total ACB score that exceeds safe thresholds.

A prospective cohort study published in the Journal of the American Geriatrics Society (N=3,434) found that patients with a cumulative ACB score of 3 or higher had a 1.46-fold increased risk of cognitive decline over 2 years compared to those scoring zero (OR 1.46, 95% CI 1.09 to 1.96) [8]. Diphenhydramine alone reaches that threshold. Adding ezetimibe does not increase the ACB score, but if the patient also takes other anticholinergic agents (oxybutynin, tricyclic antidepressants, certain antipsychotics), the total burden compounds.

A second pharmacodynamic consideration involves GI motility. Diphenhydramine slows gastrointestinal transit through its antimuscarinic effects [4]. Ezetimibe depends on intestinal absorption and enterohepatic recirculation for its efficacy [3]. Theoretically, reduced GI motility could alter the rate (though likely not the extent) of ezetimibe absorption. No published study has demonstrated a clinically meaningful change in ezetimibe efficacy from antihistamine-related GI slowing, but the mechanism is biologically plausible in patients with pre-existing gastroparesis or those taking multiple antimuscarinic agents.

Dr. Mark Donowitz, a gastroenterologist at Johns Hopkins, has noted in published commentary that "anticholinergic medications can slow small bowel transit enough to affect the absorption kinetics of orally administered drugs, particularly those with pH-dependent solubility or narrow absorption windows" [9]. Ezetimibe does not have a narrow absorption window, which limits the clinical impact of this mechanism.

Monitoring Recommendations by Patient Population

Adults Under 65 Without Comorbidities

No specific monitoring is required beyond standard lipid panel follow-up at 6 to 12 week intervals after initiating ezetimibe [10]. Patients using diphenhydramine occasionally for allergies or sleep can do so without adjusting ezetimibe dosing. Standard counseling about diphenhydramine-related drowsiness applies.

Adults 65 and Older

This population requires more attention. The AGS Beers Criteria recommend avoiding diphenhydramine in older adults regardless of concomitant medications [7]. If diphenhydramine use is unavoidable (perioperative settings, acute allergic reactions), providers should monitor for excessive sedation, urinary retention, constipation, and cognitive changes. Ezetimibe does not need dose adjustment, but lipid efficacy should be confirmed if GI motility is significantly impaired.

The 2019 Endocrine Society guideline for lipid management in older adults recommends that "clinicians reassess the benefit-risk ratio of lipid-lowering therapy at least annually in patients aged 75 and older, accounting for functional status, polypharmacy burden, and life expectancy" [10]. This principle applies when adding any new medication, including OTC antihistamines, to a regimen that includes ezetimibe.

Patients on Hepatically Metabolized Statins Plus Ezetimibe

A common clinical scenario involves patients taking ezetimibe combined with a statin (such as atorvastatin or simvastatin) who also use diphenhydramine. While the ezetimibe-diphenhydramine interaction is minimal, diphenhydramine's CYP2D6 inhibition could theoretically affect statins that use CYP2D6 as a minor pathway. In practice, atorvastatin and simvastatin depend primarily on CYP3A4, and rosuvastatin undergoes minimal CYP metabolism [11]. The three-drug combination (statin + ezetimibe + diphenhydramine) does not produce a clinically meaningful interaction for most patients.

Providers should still check for other CYP3A4 inhibitors in the medication list (clarithromycin, itraconazole, grapefruit juice in large quantities) that could raise statin levels independently of diphenhydramine.

P-glycoprotein and Transporter Considerations

Ezetimibe and its glucuronide are substrates of organic anion-transporting polypeptides (OATPs) and may interact with P-glycoprotein (P-gp) modulators [5]. Cyclosporine, a potent P-gp and OATP inhibitor, raises ezetimibe exposure by 3.4-fold, which is why the FDA label includes a specific warning about this combination [3].

Diphenhydramine has been identified as a weak P-gp inhibitor in vitro [12]. A study published in Pharmaceutical Research demonstrated that diphenhydramine inhibited P-gp-mediated efflux of digoxin in Caco-2 cell monolayers at concentrations of 100 micromolar [12]. Therapeutic plasma concentrations of diphenhydramine, however, typically reach only 0.1 to 0.3 micromolar after standard 25 to 50 mg oral doses [6]. The 300-fold gap between the in vitro P-gp inhibition concentration and the achievable plasma level makes this interaction clinically irrelevant at standard doses.

This distinction between in vitro signal and clinical significance is worth emphasizing. Patients and providers sometimes encounter database flags based on in vitro transporter data that overstate real-world risk. For ezetimibe-diphenhydramine, the P-gp interaction does not reach clinical threshold.

Patient Counseling Points

Patients asking their pharmacist or physician about this combination should receive the following guidance:

Timing is flexible. Ezetimibe can be taken at any time of day regardless of diphenhydramine dosing. No staggered administration is necessary [3].

Watch for drowsiness. Diphenhydramine causes significant sedation in most users. Ezetimibe does not. The sedation risk is from diphenhydramine alone and is not worsened by ezetimibe [4].

Report persistent GI symptoms. If a patient on ezetimibe begins using diphenhydramine regularly (rather than occasionally) and develops new constipation, it likely reflects diphenhydramine's anticholinergic effect, not an interaction with ezetimibe. Switching to a second-generation antihistamine such as cetirizine or loratadine eliminates this concern [2].

Older adults should prefer second-generation antihistamines. Cetirizine, loratadine, and fexofenadine provide equivalent histamine blockade without crossing the blood-brain barrier significantly or adding anticholinergic burden [2]. The AGS Beers Criteria specifically recommend these alternatives [7].

Do not stop ezetimibe. There is no reason to discontinue or reduce ezetimibe because of diphenhydramine use. Ezetimibe produces an average 18% reduction in LDL-C as monotherapy and a 25% additional reduction when added to a statin, per the IMPROVE-IT trial (N=18,144) [13]. Interrupting therapy over a low-risk OTC antihistamine interaction would sacrifice meaningful cardiovascular benefit.

When to Involve a Pharmacist or Prescriber

Most adults do not need a provider consultation before combining these two drugs. Situations that warrant a call include: patients with a total daily ACB score of 5 or higher from their full medication list, patients with known CYP2D6 poor-metabolizer status taking diphenhydramine alongside CYP2D6-dependent medications, patients with hepatic impairment (Child-Pugh B or C) where both drugs may have prolonged clearance, and patients who develop unexplained LDL-C increases after adding regular diphenhydramine to an ezetimibe regimen.

The IMPROVE-IT trial demonstrated that ezetimibe 10 mg added to simvastatin 40 mg reduced the composite cardiovascular endpoint (cardiovascular death, major coronary event, or nonfatal stroke) to 32.7% vs. 34.7% with simvastatin alone (HR 0.936, 95% CI 0.89 to 0.99, P=0.016) over a median 6-year follow-up [13]. Maintaining ezetimibe adherence matters. Any drug interaction concern should be resolved by switching the interacting agent, not by stopping ezetimibe.